Randomized controlled study of a novel triple nitazoxanide (<scp>NTZ</scp>)‐containing therapeutic regimen versus the traditional regimen for eradication of <i>Helicobacter pylori</i> infection

Abstract

Nitazoxanide-containing triple therapy is a promising therapy for the first-line eradication of H. pylori. (ClinicalTrials.gov Identifier: NCT02422706).